2 years ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 3%
#121 out of 5511 analysts
Average Return
+14.41%
Win Rate
41%211 out of 510
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,180.61% | $10.52 | $134.72 | 2025-05-15 - 2026-05-14 | Buy |
Celcuity IncCELC | +1,169.12% | $9.23 | $117.14 | 2025-04-11 - 2026-04-10 | Buy |
Celcuity IncCELC | +1,128.63% | $9.29 | $114.14 | 2025-04-01 - 2026-03-31 | Buy |
Celcuity IncCELC | +728.28% | $12.59 | $104.28 | 2025-02-06 - 2026-02-05 | Buy |
Celcuity IncCELC | +667.94% | $13.35 | $102.52 | 2025-06-30 - 2026-06-29 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
2 years ago
AUTL
2 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Rocket Pharmaceuticals IncRCKT | 23 | Buy | $9.00 | +158.62% | Upgrades | 2 days ago |
Lyell Immunopharma IncLYEL | 5 | Buy | $44.00 | +308.35% | Reiterates | 7 days ago |
Tscan Therapeutics IncTCRX | 10 | Hold | N/A | N/A | Downgrades | 16 days ago |
Crispr Therapeutics AgCRSP | 29 | Buy | $82.00 | +57.06% | Reiterates | 18 days ago |
Faeth Therapeutics IncFTH | 1 | Buy | $56.00 | +63.55% | Initiates Coverage On | a month ago |
Celcuity IncCELC | 27 | Buy | $140.00 | +69.53% | Maintains | a month ago |
Absci CorpABSI | 12 | Buy | $11.00 | +36.82% | Reiterates | a month ago |
Mereo Biopharma Group PLCMREO | 22 | Buy | $3.00 | +1,027.82% | Reiterates | a month ago |
Nurix Therapeutics IncNRIX | 35 | Buy | $34.00 | +35.19% | Reiterates | a month ago |
IMMIX Biopharma IncIMMX | 1 | Buy | $21.00 | +76.17% | Initiates Coverage On | 2 months ago |
Taysha Gene Therapies IncTSHA | 35 | Buy | $12.00 | +136.69% | Maintains | 3 months ago |
Cartesian Therapeutics IncRNAC | 27 | Buy | $40.00 | +405.69% | Reiterates | 3 months ago |
Artiva Biotherapeutics IncARTV | 11 | Buy | $41.00 | +376.74% | Reiterates | 3 months ago |
Nkarta IncNKTX | 19 | Buy | $11.00 | +283.28% | Reiterates | 4 months ago |
Recursion Pharmaceuticals IncRXRX | 27 | Buy | $8.00 | +150.78% | Reiterates | 4 months ago |
Autolus Therapeutics PLCAUTL | 36 | Buy | $10.00 | +434.76% | Reiterates | 5 months ago |
Sarepta Therapeutics IncSRPT | 38 | Sell | N/A | N/A | Reiterates | 6 months ago |
Solid Biosciences IncSLDB | 4 | Buy | $19.00 | +117.89% | Reiterates | 6 months ago |
Immunocore Holdings PLCIMCR | 15 | Buy | $75.00 | +137.42% | Maintains | 7 months ago |
Arcellx IncACLX | 25 | Hold | N/A | N/A | Downgrades | 7 months ago |
Amicus Therapeutics IncFOLD | 7 | Hold | N/A | N/A | Downgrades | 9 months ago |
Geron CorpGERN | 23 | Buy | $4.00 | +210.08% | Maintains | 10 months ago |
Fate Therapeutics IncFATE | 9 | Hold | N/A | N/A | Reiterates | a year ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | N/A | Reiterates | a year ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | N/A | Reiterates | a year ago |
Shattuck Labs IncSTTK | 15 | Hold | N/A | N/A | Reiterates | a year ago |
G1 Therapeutics IncGTHX | 18 | Hold | N/A | N/A | Downgrades | 2 years ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | 2 years ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 3 years ago |
Cti Biopharma CorpCTIC | 6 | Hold | N/A | N/A | Downgrades | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 3 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.